Updates are available Correction dated 2021-10-08

Article History

First Online: 6 September 2021

Change Date: 8 October 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s42255-021-00485-6

Competing interests

: M.H.T. is a member of the scientific advisory board of ERX Pharmaceuticals, Cambridge, MA, USA. He was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019. He attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016. He received funding for his research projects by Novo Nordisk (2016-2020) and Sanofi-Aventis (2012–2019). He was a consultant for Bionorica SE (2013–2017), Menarini Ricerche S.p.A. (2016) and Bayer Pharma AG Berlin (2016). As former director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018), and since 2018, as CEO of Helmholtz Zentrum München, M.H.T. has been responsible for collaborations with a multitude of companies and institutions worldwide. In this capacity, he discussed potential projects with and signed contracts for his institute(s) and the staff for research funding and/or collaborations with industry and academia worldwide, including but not limited to pharmaceutical corporations such as Boehringer Ingelheim, Eli Lilly, Novo Nordisk, MediGene, Arbormed, BioSyngen and others. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes-related patent portfolios of Helmholtz Zentrum München such as WO/2016/188932 A2 and WO/2017/194499 A1. M.H.T. confirmed that to the best of his knowledge, none of the funding sources were involved in preparing this paper. T.D.M. receives research funding by Novo Nordisk, but these funds were unrelated to the work described herein. M.K. declares no competing interests.